Featured Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key Weight regain and worsening cardiometabolic status are real threats. Too few physicians pay notice, a new viewpoint argues. By Todd Neale November 13, 2024
News Conference News AHA 2024 Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients